PMID- 34733154
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20231108
IS  - 1663-9812 (Print)
IS  - 1663-9812 (Electronic)
IS  - 1663-9812 (Linking)
VI  - 12
DP  - 2021
TI  - Comprehensive Treatment of Trans-Arterial Chemoembolization Plus Lenvatinib 
      Followed by Camrelizumab for Advanced Hepatocellular Carcinoma Patients.
PG  - 709060
LID - 10.3389/fphar.2021.709060 [doi]
LID - 709060
AB  - Aim: This study aimed to report the efficacy and safety of trans-arterial 
      chemoembolization (TACE) plus lenvatinib and camrelizumab in patients with 
      advanced hepatocellular carcinoma (HCC). Methods: This retrospective study 
      enrolled 22 patients with advanced HCC from March 2018 to December 2019. All the 
      patients received comprehensive treatment with TACE plus lenvatinib followed by 
      camrelizumab. Overall survival (OS) and progression-free survival (PFS) were 
      calculated and analysed using the Kaplan-Meier method and log-rank test. 
      Treatment response and adverse events (AEs) were also evaluated. Results: The 
      objective response rate (ORR) and disease control rate (DCR) for the whole cohort 
      were 68.2 and 100% at the first month and 72.7 and 95.5% at the third month, 
      respectively. The median OS was 24 months (95% CI, 20.323-27.677 months), and the 
      median PFS was 11.4 months (95% CI, 8.846-13.954 months). The majority of 
      treatment-related adverse reactions were mild or moderate, except for 4 that 
      developed to grade 3-4 (3 reactions of grade 3, 1 reaction of grade 4). No deaths 
      or other serious adverse reactions occurred. Conclusion: Trans-arterial 
      chemoembolization plus lenvatinib and camrelizumab shows good results 
      incontrolling tumour progression and prolonging median OS in patients with 
      advanced HCC.
CI  - Copyright (c) 2021 Liu, Li, Zhang, Lu, Sun, Wang and Han.
FAU - Liu, Juanfang
AU  - Liu J
AD  - Department of Interventional Radiology, The First Affiliated Hospital of 
      Zhengzhou University, Zhengzhou, China.
FAU - Li, Zhen
AU  - Li Z
AD  - Department of Interventional Radiology, The First Affiliated Hospital of 
      Zhengzhou University, Zhengzhou, China.
FAU - Zhang, Wenguang
AU  - Zhang W
AD  - Department of Interventional Radiology, The First Affiliated Hospital of 
      Zhengzhou University, Zhengzhou, China.
FAU - Lu, Huibin
AU  - Lu H
AD  - Department of Interventional Radiology, The First Affiliated Hospital of 
      Zhengzhou University, Zhengzhou, China.
FAU - Sun, Zhanguo
AU  - Sun Z
AD  - Department of Interventional Radiology, The First Affiliated Hospital of 
      Zhengzhou University, Zhengzhou, China.
FAU - Wang, Guozheng
AU  - Wang G
AD  - Department of Interventional Radiology, The First Affiliated Hospital of 
      Zhengzhou University, Zhengzhou, China.
FAU - Han, Xinwei
AU  - Han X
AD  - Department of Interventional Radiology, The First Affiliated Hospital of 
      Zhengzhou University, Zhengzhou, China.
LA  - eng
PT  - Journal Article
DEP - 20211018
PL  - Switzerland
TA  - Front Pharmacol
JT  - Frontiers in pharmacology
JID - 101548923
PMC - PMC8558352
OTO - NOTNLM
OT  - TACE
OT  - camrelizumab
OT  - hepatocellular carcinoma
OT  - intervention therapy
OT  - lenvatinib
COIS- The authors declare that the research was conducted in the absence of any 
      commercial or financial relationships that could be construed as a potential 
      conflict of interest.
EDAT- 2021/11/05 06:00
MHDA- 2021/11/05 06:01
PMCR- 2021/10/18
CRDT- 2021/11/04 06:21
PHST- 2021/05/14 00:00 [received]
PHST- 2021/09/10 00:00 [accepted]
PHST- 2021/11/04 06:21 [entrez]
PHST- 2021/11/05 06:00 [pubmed]
PHST- 2021/11/05 06:01 [medline]
PHST- 2021/10/18 00:00 [pmc-release]
AID - 709060 [pii]
AID - 10.3389/fphar.2021.709060 [doi]
PST - epublish
SO  - Front Pharmacol. 2021 Oct 18;12:709060. doi: 10.3389/fphar.2021.709060. 
      eCollection 2021.